Published • loading... • Updated
FDA accepts Enflonsia for kids 2 years at risk of RSV 2026
Summary by Saaz O Awaz - Listen Online
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
FDA accepts Enflonsia for kids 2 years at risk of RSV 2026
RAHWAY– Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application (sBLA) for ENFLONSIA™ (clesrovimab-cfor) to expand its indication to include prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in children under two years of age at ... Read More The post FDA accepts Enflonsi…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
